Abeona Therapeutics (ABEO) awards 113,949 restricted shares to SVP

Rhea-AI Filing Summary

Abeona Therapeutics reported an insider equity award for its SVP and Chief Legal Officer, Brendan M. O'Malley. On January 20, 2026, he received 113,949 shares of common stock as restricted stock at a price of $0.00 per share, reflecting a compensatory grant rather than an open-market purchase.

The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and the final third on January 20, 2029. Following this award, O'Malley beneficially owns 464,712 shares of Abeona Therapeutics common stock, held directly.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

O'Malley Brendan M.

(Last) (First) (Middle)

6555 CARNEGIE AVE., 4TH FLOOR

(Street)

CLEVELAND OH 44103

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
ABEONA THERAPEUTICS INC. [ ABEO ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP, Chief Legal Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/20/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/20/2026		A		113,949(1)	A	$0.00	464,712	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock will vest one-third on each of January 20, 2027, January 20, 2028, and January 20, 2029.

	/s/ Brendan O'Malley	01/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did ABEO report for Brendan M. O'Malley?

Abeona Therapeutics reported that SVP and Chief Legal Officer Brendan M. O'Malley received an award of 113,949 shares of common stock as restricted stock on January 20, 2026.

Was the ABEO insider stock award a market purchase or a grant?

The transaction was a restricted stock grant, reported at a price of $0.00 per share, indicating compensation rather than an open-market purchase.

How will Brendan M. O'Malley’s ABEO restricted stock vest?

The restricted stock will vest in three equal installments, with one-third vesting on January 20, 2027, one-third on January 20, 2028, and one-third on January 20, 2029.

How many ABEO shares does Brendan M. O'Malley own after this transaction?

After the reported restricted stock award, Brendan M. O'Malley beneficially owns 464,712 shares of Abeona Therapeutics common stock, held directly.

What is Brendan M. O'Malley’s role at Abeona Therapeutics?

Brendan M. O'Malley is an officer of Abeona Therapeutics, serving as SVP, Chief Legal Officer, as indicated in the filing.

Is the ABEO insider filing for one person or a group?

The Form 4 is filed by one reporting person, covering the holdings and transaction of Brendan M. O'Malley only.